• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

hereditary angieoedema

Biotech

Pharvaris runs tox test to reverse clinical hold for HAE asset

Pharvaris' PHA121 will undergo a six-month animal toxicity trial aimed at assuaging concerns over the med’s safety.
Ben Adams Jan 9, 2023 10:42am

Catabasis Pharmaceuticals no more: Meet Astria Therapeutics

Sep 8, 2021 9:00am

KalVista hit with a clinical hold on 2nd asset

Apr 20, 2021 8:05am

Ionis' antisense drug curbs HAE attacks in phase 2

Mar 29, 2021 9:55am

Pharvaris nabs Shire exec as new CMO

Feb 7, 2020 9:22am

Pharvaris raises $66M to push oral HAE drug through the clinic

Sep 10, 2019 11:08am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy